Hemispherian AS
PrivateLast Round
Joint Venture
Sep 29, 2025
Total Funding Raised
$10.04M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Hemispherian AS is a clinical-stage pharmaceutical company developing a novel class of small molecule drugs that target the TET2 enzyme to treat aggressive cancers.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Hemispherian AS Comparables
Compare Hemispherian AS with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Curtana Pharmaceuticals | 85% | |
| Oniria Therapeutics | 83% | |
| CV6 Therapeutics | 82% |
Hemispherian AS Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Joint Venture | Sep 29, 2025 | ||||
| Grant | Dec 15, 2023 | ||||
| Series A | Nov 24, 2022 | ||||
| VC Round | Oct 19, 2022 | ||||
| Grant | Oct 19, 2022 | ||||
Seed | May 3, 2022 |
Key People
Founding team and executive leadership
Hemispherian AS Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| European Innovation Council Fund | Grant |
| European Commission | Grant |
| Kistefos | Series A |
| Investinor | Seed |
| Meneldor | Seed, Series A |
| Kvantia | Series A |
| The Research Council of Norway | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 25, 2026
Monthly visitors increased 30% MoM.
- Apr 17, 2026
Monthly visitors increased 343% MoM.
Recent news
Latest coverage and updates
- attends_eventOct 8, 2026
Hemispherian and BioLineRx announce two GLIX1 presentations at the 31st Society for Neuro-Oncology (SNO) Annual Meeting & Education Day in Pennsylvania on Nov 12th–15th '26, featuring preclinical glioblastoma research and the design of an ongoing Phase 1/2a trial.
Hemispherian AS Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Hemispherian AS's valuation, stock price, and market status.
Is Hemispherian AS a public or private company?
Hemispherian AS is a private company.
What is the current stock price of Hemispherian AS?
Hemispherian AS is a private company, so its shares have no public market price. Caplight tracks Hemispherian AS's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Hemispherian AS worth (valuation)?
Valuation information for Hemispherian AS is not publicly available.
Can I buy Hemispherian AS stock?
Hemispherian AS shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Hemispherian AS's last funding round?
Hemispherian AS's most recent funding round was Joint Venture on September 29, 2025.
Who are the main investors in Hemispherian AS?
Key investors in Hemispherian AS include Investinor, Meneldor.
Will Hemispherian AS IPO soon?
No public IPO plans have been announced for Hemispherian AS.
How can I track Hemispherian AS secondary market activity?
Caplight tracks bids, offers, and trades in Hemispherian AS's shares on secondary markets.